A61K 40/416
Antigens related to auto-immune diseases
Official title: {Antigens related to auto-immune diseases; Preparations to induce self-tolerance}
A61K40/416 (Antigens related to auto-immune diseases) appears on 434 US grants and 1,104 published applications in this corpus.
Search patents in A61K- Granted patents
- 434
- Published applications
- 1,104
- Assignees
- 499
- Inventors
- 1,818
- Latest grant
- 22 Sep 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1989 | 1 | 0 |
| 1990 | 0 | 0 |
| 1991 | 1 | 0 |
| 1992 | 1 | 0 |
| 1993 | 0 | 0 |
| 1994 | 0 | 0 |
| 1995 | 0 | 0 |
| 1996 | 0 | 0 |
| 1997 | 6 | 0 |
| 1998 | 3 | 0 |
| 1999 | 2 | 0 |
| 2000 | 4 | 0 |
| 2001 | 2 | 2 |
| 2002 | 7 | 16 |
| 2003 | 4 | 20 |
| 2004 | 5 | 21 |
| 2005 | 1 | 18 |
| 2006 | 7 | 30 |
| 2007 | 1 | 18 |
| 2008 | 2 | 19 |
| 2009 | 8 | 22 |
| 2010 | 13 | 37 |
| 2011 | 13 | 41 |
| 2012 | 11 | 26 |
| 2013 | 13 | 33 |
| 2014 | 25 | 52 |
| 2015 | 15 | 51 |
| 2016 | 23 | 35 |
| 2017 | 20 | 60 |
| 2018 | 31 | 48 |
| 2019 | 17 | 62 |
| 2020 | 25 | 67 |
| 2021 | 26 | 70 |
| 2022 | 26 | 95 |
| 2023 | 26 | 75 |
| 2024 | 31 | 82 |
| 2025 | 39 | 60 |
| 2026 | 25 | 44 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Genetically engineered phagocytes, and related compositions, vectors, methods and systems22 Sep 2026US 12,741,025 B2The Regents of the University of California
- Microparticle-assisted Treg therapy for treatment of tissue injury and fibrosis22 Sep 2026US 12,741,026 B2University of Pittsburgh—Of the Commonwealth System of Higher Education
- Engineered regulatory T cell28 Jul 2026US 12,692,297 B2UCL Business PLC
- Populations of enriched regulatory T cells and methods for producing same28 Jul 2026US 12,692,478 B2Cellenkos, Inc.
- FOXP3 engineered CD4+ T cells for use in treg-based immunotherapy7 Jul 2026US 12,674,137 B2Fondazione Telethon
- Compositions and methods for reducing antigen-specific immunogenicity8 Oct 2026US 2026/0306626 A1The Research Foundation for The State University of New York
- Anti-cd19 car t cells for treating b-cell malignancies and autoimmune diseases8 Oct 2026US 2026/0306629 A1
- Chemoenzymatic method for the detection of cell-cell proximity interaction and isolation of tumor-specific antigen reactive t cells for immune therapy8 Oct 2026US 2026/0308537 A1The Scripps Research Institute
- Rapamycin resistant cells8 Oct 2026US 2026/0308637 A1Seattle Children's Hospital (dba Seattle Children's Research Institute)
- Populations of enriched regulatory t cells and methods for producing same1 Oct 2026US 2026/0297523 A1Cellenkos, Inc.
Most cited
By later US patents
- Method for in vitro proliferation of dendritic cell precursors and their use to produce immunogens124US 5,994,126 AThe Rockefeller University · 1999
- Culturing monocytes with IL-4, TNF-.alpha. and GM-CSF TO induce differentiation to dendric cells86US 5,849,589 ADuke University · 1998
- Method and apparatus for therapeutically treating immunological disorders and disease states75US 5,026,365 AUniversity of Massachusetts · 1991
- Sample processing system and methods67US 8,727,132 B2Miltenyi Biotec GmbH · 2014
- Active specific immune suppression57US 4,838,852 ATherakos, Inc. · 1989